A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Canagliflozin, 100 mg
DRUG: Metformin XR, 500 mg
DRUG: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
DRUG: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg

Sponsor

Janssen Research & Development, LLC